Key result
Generic valsartan/amlodipine demonstrates bioequivalence to the reference formulation under fasting and fed conditions.
Why the study?
Valsartan/amlodipine combination tablets exert synergistic antihypertensive effects, and evaluation was needed to assess the bioequivalence of a new generic formulation to the reference drug.
Is the new generic Valsartan/Amlodipine Tablet(I) bioequivalent to the reference drug in healthy Chinese volunteers?
RCT (n=72)
Open-label
1:1:1 block randomization
No
Is the new generic Valsartan/Amlodipine Tablet(I) bioequivalent to the reference drug in healthy Chinese volunteers?
A new generic formulation of valsartan/amlodipine was shown to be bioequivalent to the reference drug in healthy Chinese volunteers, supporting its regulatory approval in China.
Answers are grounded in this paper and cite their sources.
May guide formulation choices for combination antihypertensives; leaves open efficacy and safety in hypertensive patients.
Valsartan/amlodipine combination tablets can exert synergistic antihypertensive effects through different mechanisms, significantly lowering blood pressure while also addressing multiple risk factors and comorbidities in patients. This study designed a single-center, randomized, open-label, two-formulations, single-dose, three-cycle, three-sequence, partially repeated crossover controlled trial design. A total of 72 healthy Chinese volunteers participated in the fasting and fed trials, of whom 69 completed the trial process. This study employed a methodologically validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine the concentrations of valsartan and amlodipine in plasma. Phoenix WinNonlin software (version 7.0) was used to calculate pharmacokinetic parameters using a non-compartmental model. Equivalence analysis was performed using the average bioequivalence (ABE) method and the reference-scaled average bioequivalence (RSABE) method. The trial results showed that the test drug was bioequivalent to the reference drug, and no suspected serious adverse reactions or serious adverse events occurred throughout the trial. The results of this study support the launch of the new generic Valsartan/Amlodipine Tablet(I) in China. As a representative antihypertensive fixed-dose combination (FDC), these methodological insights can be directly applied to clinical trials of similar drug products, thereby enhancing success rates while mitigating development risks.Clinical trial registration: CTR20221889, ( http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml.28/07/2022 ).
No takes yet. Share an insight, caveat, or question.
Mei et al. (2025) conducted an RCT in Healthy volunteers (n=72). Valsartan/Amlodipine Tablet(I) vs. Exforge (reference drug) was evaluated on Bioequivalence (Cmax, AUC0-t, AUC0-inf). The generic Valsartan/Amlodipine 80/ tablet was bioequivalent to the reference drug under both fasting and fed conditions, with all pharmacokinetic geometric mean ratios falling within the 80.00%-125.00% acceptance range.
Synapse has enriched 10 related papers. Consider them for comparative context: